Skip to content
Peptide Science Journal
Analytical Methods

Understanding Peptide Purity: What 99% Actually Means

Almost every research peptide certificate of analysis (CoA) you’ll pick up displays a purity figure — and that figure is almost always 99% or higher. On its face, this looks like a settled question: a vial is either pure or it isn’t. But “99% purity” is a compressed phrase that hides several specific analytical decisions, and two CoAs reporting the same number can describe materially different products.

This post unpacks what HPLC purity actually measures, what that figure leaves unaccounted for, why net peptide content is the more decision-relevant number for researchers calculating dosing on a per-mass basis, what mass spectrometry adds that HPLC cannot, and what a defensible per-lot CoA from an independent laboratory actually contains. It is written for laboratory buyers evaluating research-grade material for in vitro and animal studies under institutional oversight.

If you haven’t already, the companion piece How to Read a Peptide CoA walks through the document field-by-field. This post focuses on the purity number itself.

What HPLC purity actually measures

High-performance liquid chromatography (HPLC) is the standard analytical method for assessing peptide purity. The instrument separates components of a sample as they move through a stationary phase under a controlled solvent gradient, and a UV detector — typically set at 220 nm to capture absorbance from peptide bonds — records each component as a peak in the chromatogram.

The “99%” figure on a CoA is, with few exceptions, an area-percent number. It is calculated as:

(Area of the main peak) / (Total integrated area of all peaks in the chromatogram) × 100

This is a relative measurement. It tells you that the dominant peak represents 99% of everything the detector saw under that method’s conditions. Three implications follow:

  1. Anything without a UV chromophore at the detection wavelength is invisible. That includes water, most counterions and salts, residual non-absorbing solvents, and lyoprotectant excipients such as mannitol or trehalose. None of these mass contributors appear in the HPLC integration.
  2. Anything that doesn’t elute under the method’s conditions is invisible. Strongly retained or non-eluting species — aggregates, certain hydrophobic byproducts — may not register at all if the gradient and column chemistry don’t move them through the column in the runtime.
  3. Co-eluting impurities count as part of the main peak. If a synthesis byproduct has chromatographic behavior nearly identical to the target peptide, it can hide inside the 99% rather than detract from it. This is why orthogonal methods matter.

The USP General Chapter <621> on Chromatography establishes the standard expectations for system suitability, peak integration, and reporting in pharmacopoeial chromatographic methods. A defensible peptide CoA discloses the column, the mobile phase gradient, the flow rate, the detection wavelength, and the injection conditions — not merely the resulting percent.

The takeaway: HPLC area-percent is a measure of chromatographic relative purity under the specified method. It is genuinely useful, and it is the right starting point. It is not, by itself, an absolute statement about how much of the vial’s contents are the labeled peptide.

What 99% leaves unaccounted for

A 99% HPLC purity result, by definition, allocates 1% of the integrated area to peaks other than the target. That 1% is not generic “impurity.” It is a population of related substances and process residuals, each with its own analytical and stability significance. For a peptide, the categories commonly include:

  1. Truncated sequences — peptides missing one or more residues from incomplete coupling steps during solid-phase synthesis.
  2. Deletion sequences — peptides missing an internal residue, distinct from N- or C-terminal truncation.
  3. Racemized residues — D-amino acid incorporation at stereocenters that should be L, often from base-catalyzed epimerization during coupling.
  4. Oxidized forms — particularly relevant for sequences containing methionine (Met), cysteine (Cys), or tryptophan (Trp).
  5. Deamidated forms — asparagine (Asn) converting to aspartate or iso-aspartate, and glutamine (Gln) converting to glutamate, under aqueous handling or storage conditions.
  6. Dimers and higher aggregates — disulfide-bridged or non-covalent associations, especially in cysteine-containing sequences with mishandled redox conditions.
  7. Residual synthesis byproducts — protecting group fragments, scavenger adducts, or solvent-derived modifications retained from cleavage and workup.

Which of these categories matter most depends on the sequence. For a peptide with an internal methionine, oxidation is a primary concern and the CoA should at minimum demonstrate that the bulk material is not the oxidized form. For a cysteine-containing peptide intended to fold as a monomer, dimer content matters disproportionately. For peptides rich in Asn or Gln, deamidation is a meaningful stability question.

A research-grade CoA characterizes the principal impurities where the analytical method permits, rather than reporting an undifferentiated “other peaks” line. ICH Q6A on Specifications and the AAPS literature on peptide impurity profiling both treat related-substance characterization as a core element of meaningful release testing.

Net peptide content — the metric most often overlooked

The single most common gap between what a CoA states and what a researcher dispenses comes from the difference between HPLC purity and net peptide content.

Net peptide content is the mass percentage of the lyophilized solid that is the actual peptide. The rest of the solid mass — and it is rarely negligible — typically consists of:

  • Counterion (commonly acetate, trifluoroacetate, or hydrochloride), present because the peptide was purified or isolated as a salt
  • Residual water retained after lyophilization
  • Lyoprotectant excipients (such as mannitol or trehalose) when included in the formulation

A worked example: a 10 mg vial is labeled as 99% HPLC pure with a net peptide content of 80%. The HPLC number says that of the peptide material the detector saw, 99% was the target sequence. The net peptide content says that of the 10 mg of solid in the vial, 8 mg is peptide and 2 mg is counterion, water, and excipient.

A researcher reconstituting that vial and calculating a per-mass concentration based on the vial’s label weight — without correcting for net peptide content — will be off by 20%. This is the dominant source of unintended variability in per-mass calculations across vendors, and it is invisible if you only look at the HPLC number.

USP General Chapter <1086> on Impurities in Drug Substances and Drug Products treats counterion, residual solvent, and water content as compositional facts that must be reported alongside chromatographic purity for the purity figure to be meaningfully interpreted. Net peptide content is typically determined by amino acid analysis or by elemental analysis with correction for known counterion and residual solvent. A CoA that reports HPLC purity without net peptide content is reporting only half of the relevant compositional picture.

Mass spectrometry — the identity check HPLC cannot do

HPLC answers the question “how much of the chromatogram does the main peak occupy?” It does not answer the question “what is that main peak?” The answer to the second question requires mass spectrometry (MS).

For peptides, the two standard ionization techniques are electrospray ionization (ESI-MS) and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF). Both produce spectra showing the molecular ion or its charge states — for ESI, typically [M+H]⁺, [M+2H]²⁺, and higher charge states; for MALDI, principally [M+H]⁺. The observed mass-to-charge ratios are compared against the theoretical mass calculated from the sequence and any expected modifications.

The standard acceptance criterion is that the observed mass falls within approximately ±0.5 Da of the theoretical mass for the relevant ion under low-resolution conditions, with tighter tolerances under high-resolution instruments. ICH Q2(R2) on Analytical Procedure Validation and USP General Chapter <1057> on Biotechnology-Derived Articles both treat identity confirmation by orthogonal method as a standard release expectation for sequence-defined biologic and peptide materials.

A defensible CoA does not merely state the calculated theoretical mass and a single observed number. It shows the actual mass spectrum, annotated with the observed peaks, the assigned charge states, and the calculated versus observed mass. A line that reads “Mass: confirmed” without a spectrum is, analytically, not a confirmation.

What a defensible CoA looks like

For research peptide purchasing decisions, the elements below distinguish a per-lot CoA from analytical work that has actually been performed from a templated number on a page.

| CoA Element | What it should contain | | — | — | | HPLC method | Column type and dimensions, mobile phase composition, gradient profile, flow rate, detection wavelength, injection volume | | HPLC chromatogram | The actual integrated trace, not a representative image, with axis labels and time scale | | HPLC integration table | Retention times and area percents for the main peak and each resolved impurity peak | | Mass spectrum | The actual annotated spectrum image with observed m/z, assigned charge states, and calculated vs. observed mass | | Net peptide content | Stated as a percentage, with the analytical method noted (AAA, elemental analysis, etc.) | | Counterion identity | Acetate, TFA, HCl, or other, identified explicitly | | Residual solvent | Particularly relevant when TFA is the counterion or co-residue | | Lot identifier | Matching the bottle label exactly | | Manufacturing date | Per-lot, not a generic product launch date | | Analyst signature and lab identification | The actual lab that ran the analysis, distinct from the synthesis house | | Optional but recommended | Amino acid analysis, endotoxin testing where the research use case warrants |

The pattern across these elements is the same: a defensible CoA documents the analytical evidence, not just the conclusions. The buyer can look at the chromatogram and confirm the integration; can look at the spectrum and confirm the mass; can match the lot number against the bottle in hand. Walkthroughs of this process are covered in How to Verify a Peptide Lot in 90 Seconds.

Industry context — why some “99%” CoAs aren’t real

A meaningful share of research peptide CoAs circulating in the market do not represent per-lot analytical work. Common patterns that signal a CoA is decorative rather than functional include:

  • Template CoAs reused across lots. The same chromatogram, with the same retention times and the same integration values, appears on every CoA the vendor publishes for a given product. Real per-lot analysis produces slight run-to-run variability that should be visible.
  • Synthesis-house CoAs presented as independent analysis. The lab that ran the QC is the same entity that synthesized the material. This is not automatically disqualifying, but it is not what “third-party tested” means, and the distinction should be transparent.
  • Single-method purity reporting. HPLC purity is provided with no orthogonal identity confirmation. Without mass spectrometry, the document confirms that something is 99% of a chromatogram, not that the something is the labeled peptide.
  • Purity figures with no supporting integration. A CoA states “99.2%” but provides no integration table, no impurity peaks, no chromatogram — just the number.
  • Lot number mismatches. The lot number printed on the CoA does not match the lot number on the bottle. Sometimes this is a clerical error; sometimes it indicates that the CoA was not generated for the material in hand.

The single most reliable defense against all of these patterns is a per-lot CoA from an independent analytical laboratory, published publicly and tied to the specific lot number on the bottle.

Per-lot CoA verification

A well-run vendor sends every product lot to an independent analytical laboratory before release. The resulting CoA — the HPLC chromatogram, the integration table, the annotated mass spectrum, the net peptide content, the counterion identity, and the lot-specific manufacturing data — is published in a per-lot verification portal accessible without a login.

Buyers and their internal customers can pull up the verification page, enter the lot number printed on the bottle, and retrieve the CoA that was generated for that exact lot. The CoAs are not gated behind an account. The verification page is the same document a procurement reviewer, a PI, or an institutional compliance contact would see.

This applies across the catalog, including the recovery research category and individual items such as BPC-157 10mg. The full product catalog is available on the shop page.

Closing

“99% purity” is a useful summary statistic and a poor stopping point. The decision-relevant questions for a research buyer are:

  • What method generated the 99%, and was the chromatogram disclosed?
  • What is the net peptide content, and is it stated on the CoA?
  • Was identity confirmed by mass spectrometry, with the actual spectrum shown?
  • Does the lot number on the CoA match the bottle, and is the CoA per-lot?
  • Was the analysis run by a lab independent of the synthesis house?

A CoA that answers all five questions in the affirmative is a defensible document. A CoA that only displays “99%” with no supporting analytical evidence is, regardless of the number, not.

For lot verification, see /verify/. For a structured walkthrough of CoA fields, see How to Read a Peptide CoA. For a 90-second checklist that researchers can run before opening a vial, see How to Verify a Peptide Lot in 90 Seconds.

Selected peer-reviewed and pharmacopoeial sources

  1. United States Pharmacopeia. General Chapter <621> Chromatography. USP–NF.
  2. United States Pharmacopeia. General Chapter <1086> Impurities in Drug Substances and Drug Products. USP–NF.
  3. United States Pharmacopeia. General Chapter <1057> Biotechnology-Derived Articles — Total Protein Assay. USP–NF.
  4. International Council for Harmonisation. ICH Q2(R2) Validation of Analytical Procedures. ICH Harmonised Guideline.
  5. International Council for Harmonisation. ICH Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances. ICH Harmonised Guideline.
  6. International Council for Harmonisation. ICH Q3A(R2) Impurities in New Drug Substances. ICH Harmonised Guideline.
  7. D’Hondt, M., Bracke, N., Taevernier, L., Gevaert, B., Verbeke, F., Wynendaele, E., De Spiegeleer, B. (2014). Related impurities in peptide medicines. Journal of Pharmaceutical and Biomedical Analysis, 101, 2–30.
  8. Vergote, V., Burvenich, C., Van de Wiele, C., De Spiegeleer, B. (2009). Quality specifications for peptide drugs: a regulatory-pharmaceutical approach. Journal of Peptide Science, 15(11), 697–710.

Research Use Only — Disclaimer

All compounds discussed in this article are described for laboratory and research purposes only. They are intended exclusively for in vitro experimentation and use in animal studies under appropriate institutional oversight. They are not drugs, dietary supplements, cosmetics, or food additives. They are not for human consumption and not for any therapeutic, diagnostic, preventive, or palliative purpose.

Nothing in this article constitutes medical advice. No statement should be interpreted as a recommendation that any peptide compound is safe, effective, or appropriate for any use in humans.

Buyers must be at least 21 years of age and must agree to use products strictly for research purposes.